经导管缘对缘技术(MitraClip)治疗二尖瓣反流——亚太心脏病学会(APSC)专家共识  

Asian Pacific Society of Cardiology Consensus Recommendations on the Use of MitraClip for Mitral Regurgitation

作　　者：亚太心脏病学会(APSC)专家组 潘湘斌 Asian Pacific Society of Cardiology(APSC).

机构地区：[1]不详

出　　处：《中国循环杂志》2022年第1期4-11,共8页Chinese Circulation Journal

基　　金：深圳“三名工程”(SZSM202011013);国家自然科学基金(81970444);国家高层次人才特殊支持计划(2020-RSW02);中央级公益性科研院所基本科研业务费(2019PT350005)。

摘　　要：经导管二尖瓣缘对缘修复技术(代表产品:MitraClip),是一种经导管介入途径治疗二尖瓣反流(MR)的技术,西方循证医学证据已证实MitraClip是一种有效且安全的MR介入治疗技术。但是,在亚太地区患者群体中应用该类技术及产品的随机对照试验数据仍然有限。因此,亚太心脏病学会(APSC)召集专家组,通过详细回顾现有亚太地区MitraClip文献及临床治疗证据,制定共识建议,以更好地指导亚太地区的临床医师使用MitraClip治疗MR。本专家组讨论并制定的声明包括MitraClip在各种疾病中的应用,如:退行性MR,功能性MR和其他少见的指征,例如:急性MR,动力性MR,肥厚型梗阻性心肌病和三尖瓣反流。共识声明中的每一项条目都由专家成员投票表决,只有当80%专家表决"同意"或"中立"时才予通过。经过投票表决后,共有10项共识决议被认可,以指导心脏专科医师对准备使用MitraClip进行治疗的患者进行评估与管理。Transcatheter mitral valve repair with the MitraClip,a catheter-based percutaneous edge-to-edge repair technique to correct mitral regurgitation(MR),has been demonstrated in Western studies to be an effective and safe MR treatment strategy.However,randomised clinical trial data on its use in Asian-Pacific patients is limited.Hence,the Asian Pacific Society of Cardiology convened an expert panel to review the available literature on MitraClip and to develop consensus recommendations to guide clinicians in the region.The panel developed statements on the use of MitraClip for the management of degenerative MR,functional MR,and other less common indications,such as acute MR,dynamic MR,hypertrophic obstructive cardiomyopathy,and MR after failed surgical repair.Each statement was voted on by each panel member and consensus was reached when 80%of experts voted‘agree’or‘neutral’.This consensus-building process resulted in 10 consensus recommendations to guide general cardiologists in the evaluation and management of patients in whom MitraClip treatment is being contemplated.

关 键 词：二尖瓣反流 亚太地区 MITRACLIP 缘对缘 瓣膜修复 经导管介入技术 

分 类 号：R541.4[医药卫生—心血管疾病]